||Last Updated: Nov 17th, 2006 - 22:35:04
Gene therapy study takes aim at prostate cancer
Researchers at Baylor College of Medicine (BCM) are hoping a new gene therapy that takes a gene called RTVP-1 directly into the prostate tumor will prove effective in preventing recurrence of the disease. The first phase of the study is designed to test the safety of the treatment and determine the proper dosage of gene, said Dr. Dov Kadmon, professor of urology at BCM. It will be carried out in the department of urology at BCM as well as at Ben Taub General Hospital, The Methodist Hospital and Michael E. DeBakey Veterans Affairs Medical Center.
Sep 26, 2006, 22:41
Pain associated with prostatic biopsy is related to the site biopsied
Researchers at Mayo Clinic have evaluated the major sources of pain for some men during in-office prostate biopsy and an anesthetic method that can best lessen it. Findings will be presented in two abstracts Thursday at the annual meeting of the North Central Section of the American Urological Association in San Diego.
Sep 15, 2006, 03:02
Admixture mapping reveals locus for prostate cancer risk
Harvard Medical School researchers have identified a DNA segment on chromosome 8 that is a major risk factor for prostate cancer, especially in African American men. The paper appears in the August 21 electronic edition of the Proceedings of the National Academy of Sciences.
Aug 22, 2006, 04:24
Diet modification and stress reduction may attenuate progression of prostate cancer
Statistics say that one out of six American men will develop prostate cancer and more than a third of them will experience a recurrence after undergoing treatment, putting them at high risk to die of the disease.
Aug 15, 2006, 22:18
Prostatic Irradiation Doesn’t Lead To Any Appreciable Increase in Rectal Cancer Risk
Men who receive radiation therapy for prostate cancer are not at any appreciable increased risk of developing rectal cancer compared to those not given radiation therapy, according to a new study published in the July 1, 2006, issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.
Jul 4, 2006, 00:12
Pomegranate Juice Slows PSA Acceleration Rate
Pomegranate juice packs a punch on prostate cancer that prolongs post-surgery PSA doubling time, drives down cancer cell proliferation and causes prostate cancer cells to die, according to a study published in the July 1 issue of Clinical Cancer Research. Researchers at the Jonsson Cancer Center at UCLA reported that patients with recurrent prostate cancer who drank pomegranate after surgery or radiation treatment saw their PSA blood content levels double after about 54 months. By comparison, PSA levels in the same patients prior to drinking the daily doses of eight-ounce pomegranate juice accelerated more quickly, doubling their PSA levels in only 15 months.
Jul 1, 2006, 17:33
Pomegranate juice could kill cancer cells
Drinking an eight ounce glass of pomegranate juice daily could slow the progress of prostate cancer, minimise cell damage and could also kill cancer cells, finds a new study. Researchers led by Allan Pantuck at the University of California, Los Angeles, studied 50 men who had undergone surgery or radiation treatment for prostate cancer - but had shown signs that the disease was rapidly returning.
Jul 1, 2006, 14:57
Early estrogen exposure leads to later prostate cancer risk
A study in the June 1 issue of Cancer Research presents the first evidence that exposure to low doses of environmental estrogens during development of the prostate gland in the male fetus may result in a predisposition to prostate cancer later in life.
Jun 1, 2006, 12:53
JHDM2A enzyme induced H3K9 demethylation offers new look at male hormone regulation
For the second time in less than a year, University of North Carolina at Chapel Hill scientists have purified a novel protein and have shown it can alter gene activity by reversing a molecular modification previously thought permanent.
May 7, 2006, 15:15
What is the appropriate age to stop prostate cancer screening?
Screening for prostate cancer in older men has been problematic. While this form of cancer can be fatal, it often progresses so slowly that men are more likely to die from some other disease. Aggressive treatments such as radical prostatectomy or radiation therapy may eradicate the cancer but have negative effects on quality of life. More conservative treatments may preserve quality of life, but may not be appropriate for those cases where the disease is progressing more quickly. In the face of these uncertainties, what is the appropriate age to stop screening?
May 3, 2006, 00:46
High cholesterol may contribute to prostate cancer
High cholesterol may contribute to the development of prostate cancer although further studies are needed to confirm the results, say scientists.
Apr 12, 2006, 18:11
Human infections documented with a native rodent retrovirus
Howard Hughes Medical Institute researchers and their colleagues have discovered a new retrovirus in humans that is closely related to a cancer-causing virus found in mice. Their findings describe the first documented cases of human infection with a retrovirus that is native to rodents.
Mar 31, 2006, 12:51
Alterations in DNA methylation is a better indicator of prostate cancer
Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression. They also showed that DNA hypermethylation (DNA modification without changing sequence) plays a significant role in these processes. Results of their study were published in the Feb. 15 issue of Clinical Cancer Research.
Mar 28, 2006, 21:16
Prostate treatment decisions based on perception more than fact
Men with prostate cancer generally make treatment decisions based on differences in the information they receive rather than their own preferences, according to a new review. Published in the May 1, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the review of studies in prostate cancer decision making suggests that a lack of medical evidence and consistent, comprehensive messages about therapeutic options compel men to turn to a wide variety of popular and biased sources, which influence their decision. This approach often results in treatments that do not generally reflect patients' goals.
Mar 27, 2006, 16:23
Older men with early prostate cancer survived longer with treatment vs. observation
A new study shows older men with early stage prostate cancer survive longer if they are treated versus not being treated in favor of the "watchful waiting" approach advocated by many physicians for older men with other health problems. In addition, the study revealed a survival benefit for men treated with radiation therapy making it the first study to demonstrate a survival advantage in an older population.
Feb 26, 2006, 17:31
Cabbage, cauliflower and turmeric please!
Rutgers researchers have found that the curry spice turmeric holds real potential for the treatment and prevention of prostate cancer, particularly when combined with certain vegetables
Jan 17, 2006, 01:33
Speed of PSA increase is a better prognostic marker
In the largest study of its kind to date, Mayo Clinic researchers report that prostate specific antigen (PSA) kinetics, both velocity and doubling time, can be used to predict disease progression and likelihood of death after radical prostatectomy surgery, suggesting that this could be used to guide treatment decisions.
Nov 12, 2005, 20:03
Pomegranate Juice to Combat Prostate Cancer
With more than 230,000 new cases of prostate cancer expected to be diagnosed this year alone in the U.S. and the outlook poor for patients with metastatic disease, researchers are looking for new strategies to combat the disease. Earlier research at Wisconsin and elsewhere has shown that the pomegranate, a fruit native to the Middle East, is rich in anti-oxidant and anti-inflammatory activity and is effective against tumors in mouse skin. In fact, pomegranate juice has higher anti-oxidant activity than do red wine and green tea, both of which appear promising as anti-cancer agents.
Sep 27, 2005, 21:12
EphB2 mutation linked with prostate cancer risk in african-americans
Researchers have identified a gene mutation that may increase the risk of prostate cancer up to three times in African-American men with a family history of the disease.
Sep 21, 2005, 19:10
Committee Supports New Indication for EGFR Inhibitor Erlotinib
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 to 3 in favor of recommending approval of Tarceva® (erlotinib) in combination with gemcitabine for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy. Tarceva is the first drug in a Phase III trial to have shown a significant improvement in overall survival when added to gemcitabine chemotherapy in first-line pancreatic cancer. Tarceva is an oral tablet currently approved for use in non-small cell lung cancer (NSCLC) for patients whose disease has progressed after one or more courses of chemotherapy. The FDA will now review the ODAC recommendation and a decision on Tarceva approval is anticipated by November 2, 2005.
Sep 14, 2005, 21:32
PSA remains the best indicator of cancer recurrence after surgery
Despite recent claims by some urologists that measuring the blood protein prostate-specific antigen (PSA) may not be effective in predicting risk of prostate cancer, a Johns Hopkins study of more than 2,000 men confirms that PSA remains the best measure of the likelihood of cancer recurrence after surgery.
Sep 13, 2005, 04:32
Expensive robot-assisted prostate surgery has possible benefits
Although minimally invasive prostate removal aided by a robot can lead to less blood loss, shorter hospital stays and fewer complications, there is no evidence that the procedure improves cure rates, according to a new technology assessment.
Aug 29, 2005, 22:31
Predicting prostate cancer outcome with activated Stat5 protein
Researchers from Lombardi Comprehensive Cancer Center at Georgetown University found that testing for an activated Stat5 protein in prostate tumor tissue effectively predicts which men have a form of prostate cancer that may become more aggressive and life threatening.
Aug 15, 2005, 17:47
PSA velocity shown to be associated with tumor stage
Men who have a higher rate of increase in their PSA value in the year prior to their prostate cancer diagnosis have a significantly higher risk of death following radiation therapy, according to a study in this issue of JAMA.
Jul 29, 2005, 00:47
Predicting risk of death after radical prostatectomy
Clinical factors including the time to biochemical recurrence following surgery can help predict the risk of prostate cancer death for patients following a radical prostatectomy, according to a study in the July 27 issue of JAMA
Jul 28, 2005, 23:17
Normal life after radiation for prostate cancer
Men receiving radiation therapy to combat early-stage prostate cancer are still able to achieve an erection and face a low rate of incontinence one year following treatment, according to a new study published in the July 15, 2005 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.
Jul 16, 2005, 00:00
Continuum of prostate cancer risk at all values of PSA - Study
A new study indicates there is no specific PSA value that has both high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather there is a continuum of prostate cancer risk at all values of PSA, according to a study in the July 6 issue of JAMA.
Jul 8, 2005, 13:29
Hyperthermia Therapy as a New Approach to Treat Prostate Cancer
BSD Medical Corp. (AMEX:BSM) has announced the conclusion of a highly successful conference of the 2005 annual European Society of Hyperthermic Oncology (ESHO) held in Graz, Austria, in which major breakthroughs in therapies tied to BSD's cancer treatment equipment were reported. Of the 74 presentations made at the conference, some of the highlights are being reported in several follow-up press releases.
Jun 21, 2005, 21:41
Prostate-specific Membrane Antigen Emerging as an Important Therapeutic Target to Deal with Prostate Cancer
The license provides PDC with rights to utilize the ADC technology to link cell-killing drug payloads to PDC's fully human monoclonal antibodies that target prostate-specific membrane antigen (PSMA), which is highly expressed on both primary and metastatic prostate cancer cells.
Jun 21, 2005, 10:50
Delaying radiation for prostate cancer does not affect outcome
For men diagnosed with prostate cancer, there is no risk of recurrence if external beam radiation therapy (EBRT) is delayed by several months. A study published in the July 15, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society, finds delays of EBRT had no harmful impact on clinical outcome or biochemical marker levels in low-, intermediate- and high-risk patients.
Jun 14, 2005, 06:09